What are Bacterial protein synthesis inhibitor drugs?

Bacterial protein synthesis inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Bacterial ribosome). 0 are currently marketed, with 3 more in clinical development.

Bacterial protein synthesis inhibitor

0 marketed 3 in Phase 3

This page covers all Bacterial protein synthesis inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Bacterial ribosome, Elongation factor G, isoleucyl-tRNA synthetase.

Targets

Bacterial ribosome · Elongation factor G · isoleucyl-tRNA synthetase

Phase 3 pipeline (3)

CB-183,315 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Infectious Disease
CB-183,315 is a selective inhibitor of bacterial protein synthesis that targets gram-positive pathogens by binding to the bacterial ribosome.
fusidic acid [Verutex] · Hoffmann-La Roche · Infectious diseases
Fusidic acid inhibits bacterial protein synthesis by binding to the elongation factor G.
mupirocin 2% ointment · Philippine Dermatological Society · Dermatology
Mupirocin 2% ointment works by inhibiting bacterial protein synthesis, specifically targeting isoleucyl-tRNA synthetase.